Refine by
Blood Flow Monitoring Articles & Analysis
13 news found
Rapid Medical, a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels ...
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke. “Enrolling the first patient in this landmark study is an important milestone for ...
A complication of microvascular surgery—used to reattach severed body parts such as fingers and hands by reconnecting tiny blood vessels and restoring circulation—is necrosis as a result of reduced blood flow and oxygen. The EchoSure device is designed to detect changes in blood flow to identify ...
CALCl, Italy, July 13, 2021- Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today that MMI's Symani® Surgical System was successfully used at Careggi University Hospital Florence by Prof. Marco Innocenti and his team in a complex, post-traumatic limb reconstruction that saved a patient's arm from ...
“This breakthrough technology will, for the first time, enable non-invasive on-demand Doppler measurement of blood flow, which we believe will be an essential tool for the medical ...
MILPITAS, Calif. – January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in Vascular Endotherapy ...
XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina. The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary ...
EchoSure combines 3D ultrasound imaging with advanced deep learning algorithms to automate visual and quantitative blood flow monitoring after surgery. Coupled with Sonavex’s FDA-cleared EchoMark bioresorbable markers, EchoSure eliminates the need for specialized ultrasound training in order to measure blood ...
Hansen said, “The current standard is a needle injection that monitors tissue pressure, whereas we use optics to non-invasively monitor blood flow. ...
CONSHOHOCKEN, Pa. Mar. 19, 2019 --(BUSINESS WIRE)--Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety ...
Food and Drug Administration for its EchoSureTM device to deliver definitive blood flow data on demand. The EchoSure system combines 3D ultrasound imaging with advanced deep learning algorithms to automate visual and quantitative blood flow monitoring after surgery. Coupled with Sonavex’s FDA-cleared ...
Vascuqen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. The worldwide, exclusive licenses include patent rights ...